tiprankstipranks
Advertisement
Advertisement
Senti Bio reports Q1 EPS (14c), consensus (36c)
PremiumThe FlySenti Bio reports Q1 EPS (14c), consensus (36c)
2M ago
Senti Biosciences Advances SENTI-202 With New FDA Support
Premium
Company Announcements
Senti Biosciences Advances SENTI-202 With New FDA Support
2M ago
Senti Biosciences Secures Convertible Note Financing with Celadon
Premium
Company Announcements
Senti Biosciences Secures Convertible Note Financing with Celadon
3M ago
Senti Bio completes enrollment in Phase 1 trial of SENTI-202
PremiumThe FlySenti Bio completes enrollment in Phase 1 trial of SENTI-202
5M ago
Promising Potential of SENTI-202 in Treating Acute Myeloid Leukemia: A Buy Recommendation Despite Financial Risks
Premium
Ratings
Promising Potential of SENTI-202 in Treating Acute Myeloid Leukemia: A Buy Recommendation Despite Financial Risks
7M ago
Promising Phase 1 Results and Favorable Safety Profile Drive Buy Rating for Senti Biosciences’ SENTI-202 in AML Treatment
Premium
Ratings
Promising Phase 1 Results and Favorable Safety Profile Drive Buy Rating for Senti Biosciences’ SENTI-202 in AML Treatment
7M ago
Senti Bio receives FDA RMAT designation for SENTI-202
PremiumThe FlySenti Bio receives FDA RMAT designation for SENTI-202
7M ago
Senti Bio announces new data from trial of SENTI-202
Premium
The Fly
Senti Bio announces new data from trial of SENTI-202
7M ago
Buy Rating for Senti Biosciences: Innovative Gene Circuit Platform Shows Promise in AML Treatment
Premium
Ratings
Buy Rating for Senti Biosciences: Innovative Gene Circuit Platform Shows Promise in AML Treatment
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100